evofosfamide + docetaxel

**Evofosfamide + docetaxel** is an investigational combination therapy composed of evofosfamide and docetaxel, evaluated primarily for cancer, especially non-small cell lung cancer in preclinical models. **Evofosfamide** (TH-302) is a hypoxia-activated prodrug that, under low oxygen conditions common in tumors, releases bromo-isophosphoramide mustard (Br-IPM), a DNA alkylating agent that induces cell death in hypoxic tumor regions. **Docetaxel** is a well-established chemotherapeutic agent that acts by stabilizing microtubules, thereby preventing cell division. The combination aims to leverage evofosfamide's selective targeting of hypoxic tumor zones with docetaxel's cytotoxicity against dividing cancer cells. The combined regimen demonstrates superior or additive antitumor efficacy and a favorable safety profile compared to other regimens like ifosfamide + docetaxel, with reduced hematologic toxicity[1][3][7].

Other names

evofosfamide + docetaxelTH-302 + docetaxel